Gene expression assay for measurement of dna mismatch repair deficiency
AssigneeBruker Spatial Biology, Inc.
InventorsPatrick DANAHER, Sarah WARREN
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to methods using gene expression measurements to identify mismatch repair deficiency, microsatellite instability and hypermutation in a subject.
Claims24
A method of treating cancer in a subject identified as having mismatch repair deficiency, the method comprising administering to the subject identified as having mismatch repair deficiency at least one treatment, wherein the subject is identified as having mismatch repair deficiency by a method comprising
- a) measuring the gene expression level of at least one gene comprising MLH1, MSH2, MSH6 or PMS2 in a tumor sample from the subject;
- b) determining for each of the at least one gene a score Z, wherein Z=(x−μ1)/σ1, wherein x is the log-transformed normalized expression of the at least one gene, μ1 is the mean of the log-transformed normalized expression of the at least one gene in non-hypermutated samples, and σ1 is the standard deviation of the log-transformed normalized expression of the at least one gene in non-hypermutated samples;
- c) determining a score MLS, wherein MLS=(Zm+c1)/c2, wherein Zm is the minimum Z score of the at least one gene, and wherein
- c1 is 0 and c2 is 1 when one gene is used,
- c1 is 0.56 and c2 is 0.83 when two genes are used,
- c1 is 0.85 and c2 is 0.75 when three gene are used, or
- c1 is 1.03 and c2 is 0.70 when four genes are used;
- d) comparing the MLS score with a predetermined cutoff value, wherein the cutoff value identifies mismatch repair deficiency in a subject with at least 95% specificity;
- and
- e) identifying the presence of mismatch repair deficiency in the subject when the MLS score is equal to or greater than the predetermined cutoff value.
(canceled)
A method of treating cancer in a subject identified as having mismatch repair deficiency, the method comprising administering to the subject identified as having mismatch repair deficiency at least one treatment, wherein the subject is identified as having mismatch repair deficiency by a method comprising
- a) measuring the gene expression level of at least one gene comprising EPM2AIP1, TTC30A, SMAP1, RNLS, WNT11, SFXN1, SREBF1, TYMS, EIF5AL1, or WDR76 in a tumor sample from the subject;
- b) determining a score HPS, wherein HPS=(y−μ2)/σ2, wherein y=Σi=110yiwi, wherein yi is the log-transformed normalized expression of the at least one gene i in the tumor sample and wi is the prespecified weight for gene i, μ2 is the mean of the linear combination of the log-transformed normalized expression of the at least one gene in non-hypermutated samples, and σ2 is the standard deviation of the linear combination of the log-transformed normalized expression of the at least one gene in non-hypermutated samples;
- c) comparing the HPS score with a predetermined cutoff value, wherein the cutoff value identifies mismatch repair deficiency in a subject with at least 95% specificity;
- and
- d) identifying the presence of mismatch repair deficiency in the subject when the HPS score is equal to or greater than the predetermined cutoff value.
(canceled)
-32. (canceled)
(canceled)
Dependencies are inferred from the claim text.